Silver Book Fact

Use of an epidermal growth factor inhibitor in the treatment of metastatic colon cancer patients without the KRAS gene mutation saw survival rates of 15.6 months, compared to 5.6 months in those without the mutation.

Lievre, A, J Bachet, V Boige, A Cayre, D LeCorre, E Buc, et al. KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab. J Clin Oncol. 2008; 26(3): 374-9. http://www.ncbi.nlm.nih.gov/pubmed/18202412

Reference

Title
KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab
Publication
J Clin Oncol
Publication Date
2008
Authors
Lievre, A, J Bachet, V Boige, A Cayre, D LeCorre, E Buc, et al
Volume & Issue
Volume 26, Issue 3
Pages
374-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Use of the Pap smear test is credited with cutting the age-adjusted cervical cancer incidence in half between 1975 and 2001, reducing it from 14.8 to 7.9 cases per 100,000…  
  • Since the war on cancer was declared in 1971, our arsenal has tripled. New drugs accounted for around 50-60% of the increase in six-year cancer survival rates since 1975.…  
  • From 2007 to 2011, lung cancer incidence rates decreased by three percent each year in men and 2.2 percent each year in women.  
  • Investments in cancer care generated $598 billion of additional value for cancer patients diagnosed between 1983 and 1999.  
  • Improvements in surgical techniques and combination therapies increased the 1-year survival rate for lung cancer from 34 percent in 1975-1977 to 45 percent in 2006-2009.